The Supreme Court on Monday reserved its order on a PIL seeking public disclosure of COVID-19 vaccine clinical trial data and post-vaccination data which claimed that it is mandatory and required that the government must publish the data "as per international medical norms".
A bench, headed by Justice L Nageswara Rao, reserved the judgement after hearing arguments from counsels of all the parties.
The plea was filed by Dr Jacob Puliyel alleging coercive vaccination of citizens and seeking disclosure of COVID-19 vaccine clinical trial data and post-vaccination data.
The Central government had earlier filed the affidavit on the plea saying that any "misgivings and misconceived doubts and motivated propaganda" against COVID-19 vaccination can only result in a potential threat of increasing vaccine hesitancy, which will not be in the public interest.
It had said such a plea goes against national interest and would violate the rights of citizens to get vaccinated against the virus.
The affidavit had pointed out that there is a statutory regime in place for trial and approval of vaccines and that the same has been followed.
All vaccination trial data is in public, except the data that would expose any information about the participants of the clinical trial, which is against rules and guidelines, it had added
The plea has raised a false alarm and warning against efforts of the nation to combat an unprecedented tragedy faced by the human race, said the Centre seeking dismissal of the plea.
The PIL sought direction for transparency in clinical trial data for the COVID-19 vaccines being administered in India under emergency use.
Dr Puliyel had also sought a stay on the COVID-19 vaccine mandates that are being issued by authorities in various parts of the country.
He had also said that the Helsinki and World Health Organization (WHO) mandated that all COVID-19 vaccine data and trials have to be in a transparent manner, which, in this case, was not made.
The plea sought direction to the Centre to disclose the reasoned decision of the DCGI granting approval or rejecting an application for emergency use authorization of COVID-19 vaccines and to also disclose the post-vaccination data regarding the adverse impact of vaccines -- who got infected, who needed hospitalization and those who died after such infection post-COVID-19 vaccination.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)